Analysts Set Cardiff Oncology, Inc. (NASDAQ:CRDF) Target Price at $8.75

Shares of Cardiff Oncology, Inc. (NASDAQ:CRDF) have earned a consensus rating of “Hold” from the nine analysts that are currently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and four have issued a buy rating on the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $8.75.

A number of equities research analysts have recently commented on the company. TD Cowen downgraded Cardiff Oncology from a “buy” rating to a “hold” rating in a research report on Monday, June 1st. Piper Sandler lowered their price objective on Cardiff Oncology from $10.00 to $6.00 and set an “overweight” rating for the company in a research report on Wednesday, February 25th. Wall Street Zen downgraded Cardiff Oncology from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. HC Wainwright downgraded Cardiff Oncology from a “buy” rating to a “neutral” rating in a research report on Monday, June 1st. Finally, Craig Hallum downgraded Cardiff Oncology from a “buy” rating to a “hold” rating and set a $2.00 price target for the company. in a research report on Wednesday, June 3rd.

Institutional Investors Weigh In On Cardiff Oncology

A number of institutional investors have recently added to or reduced their stakes in the company. Laurion Capital Management LP grew its position in Cardiff Oncology by 7.3% during the fourth quarter. Laurion Capital Management LP now owns 2,646,738 shares of the company’s stock valued at $7,437,000 after acquiring an additional 180,866 shares during the period. Acorn Capital Advisors LLC grew its position in Cardiff Oncology by 39.3% during the third quarter. Acorn Capital Advisors LLC now owns 1,962,084 shares of the company’s stock valued at $4,042,000 after acquiring an additional 553,317 shares during the period. Geode Capital Management LLC grew its position in Cardiff Oncology by 7.5% during the second quarter. Geode Capital Management LLC now owns 1,498,838 shares of the company’s stock valued at $4,723,000 after acquiring an additional 104,409 shares during the period. Franklin Resources Inc. purchased a new stake in Cardiff Oncology during the fourth quarter valued at about $3,388,000. Finally, State Street Corp grew its position in Cardiff Oncology by 4.0% during the fourth quarter. State Street Corp now owns 1,191,647 shares of the company’s stock valued at $3,349,000 after acquiring an additional 45,288 shares during the period. Hedge funds and other institutional investors own 16.29% of the company’s stock.

Cardiff Oncology Price Performance

Shares of NASDAQ:CRDF opened at $1.54 on Wednesday. The company has a market cap of $105.29 million, a P/E ratio of -2.30 and a beta of 1.36. Cardiff Oncology has a 52 week low of $1.35 and a 52 week high of $4.56. The business has a fifty day simple moving average of $1.66 and a 200-day simple moving average of $2.01.

Cardiff Oncology (NASDAQ:CRDF) last announced its quarterly earnings data on Thursday, May 14th. The company reported ($0.18) EPS for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.05). The business had revenue of $0.04 million during the quarter, compared to analysts’ expectations of $0.09 million. Cardiff Oncology had a negative net margin of 8,527.43% and a negative return on equity of 95.51%. Sell-side analysts expect that Cardiff Oncology will post -0.66 earnings per share for the current fiscal year.

About Cardiff Oncology

Cardiff Oncology, Inc is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts. The company is dedicated to the discovery, development and commercialization of novel small-molecule therapies designed to modulate the tumor microenvironment and enhance antitumor immune responses. By focusing on unique immuno-oncology targets, Cardiff seeks to address resistance pathways that limit the effectiveness of existing cancer treatments.

Cardiff’s pipeline comprises several small-molecule immunomodulators in various stages of preclinical and clinical development.